Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Green Cross, LG Life Sciences Team Up To Sell Osteoarthritis Drug To Compete With Pfizer's Celebrex

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Korea vaccine leader Green Cross Corp. and LG Life Sciences Ltd. have teamed up to co-promote Shinbaro, a first-line osteoarthritis treatment developed by Green Cross that could compete against Pfizer Inc.'s Celebrex
Advertisement

Related Content

Green Cross Concludes Takeover Deal Of Innocell; Looks To Overseas Markets For Growth
Korea Tries To Buffer Heavy Price Cuts With R&D Incentives, But Local And Global Pharma Up In Arms
Green Cross Is Latest Korean Pharma To Struggle Under Regulatory Headwinds
Merck Turns Again To Daewoong For Co-promotion In South Korea
South Korea's LG Takes Shot At Vaccines Via In-licensing Deal With U.S. Novavax
2011 Preview: Will Korean Pharmas Follow Japanese Pharmas Lead To Survive Harsh Environment At Home?
2011 Preview: Will Korean Pharmas Follow Japanese Pharmas Lead To Survive Harsh Environment At Home?
Green Cross To Focus On Biobetters As Korean Biosimilar Space Gets Crowded: Bio Korea Conference
Advertisement
UsernamePublicRestriction

Register

SC078850

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel